Treatment of Uterine Sarcoma in NTRK Fusion-Positive Gynecological Sarcoma

This protocol addresses uterine sarcoma arising in the specific setting of NTRK fusion-positive gynecological sarcoma — a rare molecular subgroup with distinct pathological features that shapes the treatment approach.

NTRK fusion-positive gynecological sarcomas are rare spindle cell tumors resembling fibrosarcomas. Their molecular profile distinguishes them from other uterine sarcoma subtypes and directly informs clinical decision-making.

For localized disease, the primary management strategy centres on a surgical approach. The full protocol — including eligibility criteria, procedural specifications, and the complete evidence-based algorithm — is available through the link below.

Complete regimen details are accessible via the structured protocol.